Evidence map›Paper›PMID 41251715›Full record

ArticleInnere Medizin (Heidelberg, Germany)2026

[An unusual cause for kidney transplantation].

Phillip Kremer, Thorsten Wiech, Ina Kötter, Malte Kluger, Tobias Huber, Martin Krusche, Tingting Xiong

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Phillip KremerIII. Medizinische Klinik, Sektion für Rheumatologie und entzündliche Systemerkrankungen, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland. p.kremer@uke.de.
Thorsten WiechInstitut für Pathologie, Sektion Nephropathologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Ina KötterIII. Medizinische Klinik, Sektion für Rheumatologie und entzündliche Systemerkrankungen, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
Malte KlugerIII. Medizinische Klinik, Nephrologie und Transplantationsmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Tobias HuberIII. Medizinische Klinik, Nephrologie und Transplantationsmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Martin KruscheIII. Medizinische Klinik, Sektion für Rheumatologie und entzündliche Systemerkrankungen, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
Tingting XiongIII. Medizinische Klinik, Sektion für Rheumatologie und entzündliche Systemerkrankungen, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic amyloidoses are a heterogeneous group of rare diseases characterized by deposition of misfolded proteins. Amyloid A (AA) amyloidosis results from chronic inflammatory processes, with autoinflammatory diseases-particularly familial Mediterranean fever (FMF)-representing one of the most common causes. Genetic autoinflammatory diseases should be considered in the differential diagnosis, especially in patients from high-prevalence regions with unexplained renal insufficiency. CASE REPORT: The case of a 50-year-old female patient of Armenian origin who underwent kidney transplantation in 2022 for end-stage renal failure of unknown etiology is reported. Despite adequate immunosuppression, she developed progressive graft dysfunction with increasing proteinuria. In addition, persistently elevated serological inflammatory markers were observed, but without accompanying clinical symptoms. Repeat transplant biopsy ultimately revealed glomerular amyloid deposits on Congo red staining, and immunohistochemistry confirmed AA amyloidosis. Genetic analysis demonstrated compound heterozygosity in the Met694Val/Val726Ala (MEFV) gene. A diagnosis of familial Mediterranean fever type II with systemic amyloidosis was established, and anti-inflammatory therapy with colchicine was initiated. Type II FMF typically follows a primarily subclinical course and first manifests through the development of systemic, most commonly renal, AA amyloidosis.

conclusionThis case highlights the need for a thorough differential diagnostic work-up in progressive renal failure of unknown etiology combined with persistent serological inflammation. In end-stage renal failure of unknown cause and systemic inflammatory signs, rare conditions such as AA amyloidosis should also be considered. Genetic testing for FMF may be useful, particularly in the presence of familial or ethnic predisposition.

Indexed as

AmyloidosisFamilial Mediterranean FeverKidney Failure, ChronicKidney TransplantationDiagnosis, DifferentialFemaleHumansMiddle AgedPyrinSerum Amyloid A ProteinPyrinSerum Amyloid A ProteinAutoinflammatory diseaseChronic kidney diseaseGeneticsInflammationRare diseasen

Identifiers

PMID41251715
PMCPMC13132935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.